Better Buy: Gilead Sciences vs. Pfizer

You might think that Gilead Sciences (NASDAQ: GILD) and Pfizer (NYSE: PFE) would have delivered tremendous gains in 2020. After all, Gilead launched a much-heralded treatment for COVID-19 with Veklury (remdesivir), and Pfizer rolled out an even more anxiously awaited coronavirus vaccine. But neither of these stocks performed well last year. Gilead's shares sank 10%, while Pfizer's shares slipped nearly 1%.

The past is the past, though. Which of these stocks is the better pick moving forward? Here's how Gilead and Pfizer stack up against each other.

Image source: Getty Images.

Continue reading

Source Fool.com